Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

96.63USD
13 Jul 2018
Change (% chg)

$1.02 (+1.07%)
Prev Close
$95.61
Open
$94.96
Day's High
$96.86
Day's Low
$94.94
Volume
799,802
Avg. Vol
1,946,128
52-wk High
$125.84
52-wk Low
$69.40

Latest Key Developments (Source: Significant Developments)

Abbvie Says It Submitted Supplemental NDA To U.S. FDA For Venetoclax
Thursday, 12 Jul 2018 

July 12 (Reuters) - AbbVie Inc ::ABBVIE ANNOUNCES SUBMISSION OF SUPPLEMENTAL NEW DRUG APPLICATION TO US FDA FOR VENETOCLAX IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY.  Full Article

Abbvie Inc - Director Glenn Tilton Reports Open Market Purchase Of 5,400 Shares Of Common Stock
Saturday, 30 Jun 2018 

June 29 (Reuters) - AbbVie Inc ::ABBVIE INC SAYS DIRECTOR GLENN TILTON REPORTS OPEN MARKET PURCHASE OF 5,400 SHARES OF COMMON STOCK AT AVERAGE PRICE OF $91.90PER SHARE ON JUNE 27 - SEC FILING.  Full Article

Imbruvica (Ibrutinib) Supplemental New Drug Application Accepted For Review By U.S. FDA
Monday, 25 Jun 2018 

June 25 (Reuters) - AbbVie Inc ::IMBRUVICA® (IBRUTINIB) SUPPLEMENTAL NEW DRUG APPLICATION ACCEPTED FOR REVIEW BY U.S. FDA WITH POTENTIAL TO BROADEN TREATMENT USE AS A COMBINATION TREATMENT OPTION WITH RITUXIMAB IN WALDENSTRÖM'S MACROGLOBULINEMIA (WM), A RARE FORM OF BLOOD CANCER.ABBVIE INC - SNDA BASED ON DATA FROM PHASE 3 INNOVATE STUDY, SUGGESTING IMBRUVICA PLUS RITUXIMAB MAY IMPROVE OUTCOMES ACROSS ALL LINES OF WM.  Full Article

AbbVie And Calibr Announce Collaboration For Next Gen T-Cell Therapies
Monday, 25 Jun 2018 

June 25 (Reuters) - AbbVie Inc ::ABBVIE AND CALIBR ANNOUNCE COLLABORATION FOR NEXT GENERATION T-CELL THERAPIES.ABBVIE INC - COLLABORATION WILL FOCUS ON SWITCHABLE CAR-T THERAPIES AIMED PRIMARILY AT SOLID TUMORS.ABBVIE - WILL PAY CALIBR UPFRONT LICENSE FEE AND GAIN EXCLUSIVE ACCESS TO CALIBR'S SWITCHABLE CAR-T PLATFORM FOR A TERM OF UP TO FOUR YEARS.ABBVIE INC - ALSO HAS OPTION TO DEVELOP ADDITIONAL CELL THERAPIES TOWARD ABBVIE-NOMINATED TARGETS.ABBVIE - ALSO HAS OPTION TO LICENSE EXISTING CALIBR CELL THERAPY PROGRAMS UNDER DEVELOPMENT FOR HEMATOLOGICAL & SOLID CANCERS.  Full Article

FDA Approves Abbvie & Genentech USA's VENCLEXTA For Treating Two Types Of Blood Cancers
Friday, 8 Jun 2018 

June 8 (Reuters) - U.S. Food and Drug Administration::U.S. FDA SAYS APPROVED ABBVIE & GENENTECH USA'S VENCLEXTA FOR TREATING PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA.  Full Article

AbbVie Inc Says On May 17, Entered Loan Credit Agreement To Borrow Up To $3 Bln
Saturday, 19 May 2018 

May 18 (Reuters) - AbbVie Inc ::ABBVIE INC - ON MAY 17, ENTERED TERM LOAN CREDIT AGREEMENT TO BORROW TERM LOANS ON AN UNSECURED BASIS OF UP TO $3 BILLION - SEC FILING.  Full Article

Abbvie Submits Marketing Authorization Application To EMA For Investigational Treatment Risankizumab For Moderate To Severe Plaque Psoriasis
Tuesday, 1 May 2018 

May 1 (Reuters) - AbbVie Inc ::ABBVIE SUBMITS MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR INVESTIGATIONAL TREATMENT RISANKIZUMAB FOR MODERATE TO SEVERE PLAQUE PSORIASIS.ABBVIE INC - APPLICATION SUPPORTED BY FOUR PIVOTAL PHASE 3 TRIALS EVALUATING MORE THAN 2,000 PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS.  Full Article

Abbvie Announces Positive Results From Second Phase 3 Study Of Elagolix In Women With Uterine Fibroids
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Abbvie Inc ::ABBVIE ANNOUNCES POSITIVE TOPLINE RESULTS FROM SECOND PHASE 3 STUDY EVALUATING INVESTIGATIONAL ELAGOLIX IN WOMEN WITH UTERINE FIBROIDS.ABBVIE INC - ‍SECOND OF TWO PIVOTAL PHASE 3 STUDIES (ELARIS UF-II) MET PRIMARY EFFICACY ENDPOINT AND ALL RANKED SECONDARY ENDPOINTS​.ABBVIE INC - ‍RESULTS WERE CONSISTENT WITH FIRST PHASE 3 STUDY​.ABBVIE INC - STUDY ALSO MET ALL RANKED SECONDARY ENDPOINTS (P<0.02) AT MONTH SIX.ABBVIE INC - ‍RESULTS DEMONSTRATED ELAGOLIX, WITH LOW-DOSE ADD-BACK THERAPY, REDUCED HEAVY MENSTRUAL BLEEDING COMPARED TO PLACEBO​.ABBVIE INC - ‍WOMEN IN STUDY WILL CONTINUE IN EITHER POST-TREATMENT FOLLOW-UP OR A BLINDED SIX-MONTH EXTENSION STUDY​.  Full Article

FDA accepts Novartis submission of biosimilar version of Humira
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Novartis AG ::SANDOZ REGULATORY SUBMISSION FOR PROPOSED BIOSIMILAR ADALIMUMAB ACCEPTED BY FDA.US FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTED ITS BIOLOGICS LICENSE APPLICATION (BLA), SUBMITTED UNDER THE 351 (K) PATHWAY, FOR PROPOSED BIOSIMILAR ADALIMUMAB TO THE REFERENCE MEDICINE, HUMIRA.‍DATA PACKAGE PROVIDED IS EXPECTED TO DEMONSTRATE THAT SANDOZ PROPOSED BIOSIMILAR ADALIMUMAB MATCHES REFERENCE BIOLOGIC MEDICINE IN TERMS OF SAFETY, EFFICACY AND QUALITY​.  Full Article

Abbvie Looking To Return Additional Cash To Shareholders
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Abbvie Inc ::ABBVIE CEO SAYS ANTICIPATES REDUCTION IN TAX RATE AS RESULT OF US TAX REFORM.ABBVIE CEO PLANS TO MAKE SIGNIFICANT INVESTMENT IN US IN COMING YEARS WITH ACCESS TO OVERSEAS CASH.ABBVIE CEO SAYS PLANS TO ADVANCE NEUROSCIENCE PIPELINE TO CONTRIBUTE TO SALES GROWTH IN COMING DECADE.ABBVIE CEO SAYS RISANKIZUMAB FOR PSORIASIS AND RELATED INDICATIONS CAN BE $5 BILLION DRUG BY 2025.ABBVIE CEO SAYS UPADACITINIB IMMUNOLOGY DRUG CAN REACH $6.5 BILLION SALES BY 2025 WITH SIX INDICATIONS.ABBVIE SAYS EXPECTS TO MOVE AT LEAST 10 DRUGS FOR SOLID TUMOR CANCERS TO CLINICAL TRIALS IN NEXT 12 MONTHS.ABBVIE CEO SAYS WILL LOOK FOR WAYS TO RETURN ADDITIONAL CASH TO SHAREHOLDERS.  Full Article

Photo

AbbVie wins reversal of $140 million verdict in case over AndroGel risks

A U.S. judge on Thursday overturned a $140.1 million verdict against AbbVie Inc in a lawsuit by a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack.